

Thymosin β 4 and Cardiac Regeneration: Are We Missing a Beat?

David C. Gajzer · Jerome Balbin · Hina W. Chaudhry

Published online: 25 May 2012
© Springer Science+Business Media, LLC 2012

Abstract Epicardial resident stem cells are known to differentiate into cardiomyocytes during cardiac development, amongst other cell types. Whether epicardium-derived progenitor cells (EPDCs) retain this plasticity in the adult heart has been the topic of heated scientific debate. Priming with thymosin beta 4, a peptide which has been suggested to be critical for cardiac development and to have cardio-protective properties, was recently shown to induce differentiation of EPDCs into cardiomyocytes in a small animal model of myocardial infarction. This finding is in stark contrast to another recent study in which thymosin beta 4 treatment following myocardial infarction did not induce cardiomyocyte differentiation of EPDCs. While EPDCs seem to exhibit overall cardio-protective effects on the heart following myocardial infarction, they have not been shown to differentiate into cardiomyocytes in a clinically relevant setting. It will be important to understand why the ability of one therapeutic agent to induce cardiomyocyte differentiation of EPDCs seemingly depends on a single variable, i.e. the time of administration. Furthermore, in light of a recent report, it appears that thymosin beta 4 may be dispensable for cardiac development.

Keywords Stem cells · Progenitor cells · Cardiac development · Ischemic biology–basic studies · Myogenesis

Funding Information Grant: HL088255, NIH-NHLBI

D. C. Gajzer · J. Balbin · H. W. Chaudhry (✉)
Cardiovascular Regenerative Medicine, Cardiovascular Research
Center, Mount Sinai School of Medicine,
One Gustave L. Levy Place, Box 1030, New York, NY 10029,
USA
e-mail: hina.chaudhry@mssm.edu

D. C. Gajzer
e-mail: david.gajzer@mssm.edu

J. Balbin
e-mail: balbinjb@umdnj.edu

Introduction

Heart disease is the leading cause of death worldwide [1]. This is due to the fact that the human heart does not possess clinically significant ability to regenerate in response to injury, such as myocardial infarction [2]. Cardiomyocytes, the basic unit of the heart muscle, exit the cell cycle shortly after birth and remain in a quiescent state indefinitely [3]. Efforts in the field of cardiac regenerative medicine have focused on the use of stem cells, both non-resident and resident within the heart, in an attempt to generate new cardiomyocytes. So far, efforts to transplant stem cells have not resulted in adequate and sustained improvement in cardiac hemodynamics, nor evidence of actual cardiomyocyte differentiation arising from such cells.

This review aims to provide an overview of recent stem cell-based studies in cardiac regenerative medicine. Epicardium-derived progenitor cells, a cardiac progenitor cell type resident in the outermost layer of the heart [4] and thymosin beta 4, a peptide that has been suggested to be critical for cardiac development [5] and to have cardio-protective and–regenerative effects [6, 7], are discussed in detail as an excellent example of why it is crucial to avoid premature assumptions regarding the regenerative capacity of any given cell type or factor. Furthermore, a step-wise approach to testing candidate cell types and factors is outlined to ensure true regenerative potential.

Cardiac Regenerative Capacity

The mammalian heart has very limited regenerative capacity [3]. In mammals, cardiomyocytes exit the cell cycle shortly after birth and remain in a quiescent state indefinitely [2]. In

humans, the heart was traditionally believed to be a post-mitotic organ with a predetermined number of cardiomyocytes established at birth and preserved throughout life [8]. More recently, evidence of cardiomyocyte turnover in humans was found, and the numbers reported vary significantly. One recent study based on retrospective carbon 14 (^{14}C) birth dating of cells reported that the frequency of annual cardiomyocyte renewal ranges from 1 % in young adults to 0.45 % in the elderly [9]. These findings conflict with reports on the level of apoptosis in the adult human heart [10] and the progressive increase in cardiomyocyte turnover associated with aging [11, 12], ranging from 10 % to 40 % per year in female hearts 20 to 100 years of age and 7 % to 32 % per year in male hearts, respectively. These data indicate that the cardiomyocyte compartment is replaced 15 times in women and 11 times in men from age 20 to 100 [12]. Despite this evidence of cardiomyocyte turnover in the healthy adult heart, cardiac regeneration in response to injury, such as myocardial infarction, is very limited and its mechanisms are not well understood. A genetic pulse-chase experiment in mice using tamoxifen-induced Cre activation of a reporter marker traced its dilution following myocardial infarction and demonstrated that up to 18 % of cardiomyocytes present in the heart 3 months after infarction arose de novo from the infarct border zone, from a cell source intrinsic or extrinsic to the heart [13], and not from preexisting myocytes, as is the case in teleost fish [14].

Non-Resident Stem Cells

Investigators in cardiac regenerative medicine have tried to make use of a variety of stem cell populations, both intrinsic and extrinsic to the heart. For example, the question of whether bone marrow-derived cells (BMCs), in particular hematopoietic stem cells, can contribute to cardiac repair by transdifferentiation into cardiomyocytes [15, 16] has been the topic of heated scientific debates for years, as they were initially thought to differentiate into cardiomyocytes following transplantation [17–19] but later shown to rather adopt mature hematopoietic fates [20] and generate a small number of cardiomyocytes through cell fusion, rather than transdifferentiation [15]. The ability of autologous bone marrow-derived cells to improve cardiac function following myocardial infarction was tested in several large clinical trials in which BMCs were administered into the coronaries of patients suffering from acute myocardial infarction [21–23]. While a subset of patients in the REPAIR-AMI trial showed a 3 % increase in ejection fraction, the ASTAMI trial did not demonstrate any beneficial effect on left ventricular function. These contradictory results support the notion that BMCs may not be as promising a cell type as was originally thought.

Resident Cardiac Stem Cells

Endogenous cardiac stem cells are currently in the limelight as the study of this diverse group of cells that reside in the adult heart holds the promise of cardiac repair without the limitations and risks associated with BMCs. Several populations of cells resident in the adult heart have been identified. Although there is no definitive consensus yet on the markers that precisely define these cell populations, they are reported to share a set of cardiogenic markers including GATA-4, NKX2.5, TBX5 and MEF2c [24]. The markers used for enrichment are also used to group this diverse set of progenitor cells.

C-kit⁺ cells were originally isolated from the adult rat heart and have been reported to adopt myogenic, endothelial and smooth muscle cell lineages in vitro, and to differentiate into cardiomyocytes, smooth muscle cells and vascular endothelium when engrafted into acutely ischemic myocardium [25, 26]. Transplantation of c-kit⁺ cells in animal models of post-myocardial infarction heart failure has proven effective in alleviating left ventricular remodeling and improving left ventricular function in acute and chronic myocardial infarctions [25–29]. Furthermore, initial results of the ongoing “Stem Cell Infusion in Patients with Ischemic cardiomyopathy (SCIPIO)” trial are encouraging [30]. Intracoronary infusion of autologous c-kit⁺ cells in patients with myocardial infarction and left ventricular ejection fraction <40 % resulted in significant long-term improvement of left ventricular ejection fraction and reduction in infarct size post coronary artery bypass grafting (CABG), whereas left ventricular ejection fraction and infarct size in control patients who had undergone CABG only did not change. *Islet-1*⁺ cardiac progenitor cells were first identified in post-natal rat, mouse and human myocardium [31, 32], and were recently shown to be able to differentiate into cardiac, smooth muscle and endothelial cells when isolated from neonatal mouse heart [33]. *Sca-1*⁺ cells were first isolated from the adult mouse heart in 2003 and have been reported to express cardiac-specific markers in vitro in the presence of 5'-azacytidine. When administered intravenously following cardiac ischemia and subsequent reperfusion, Sca-1⁺ cells were shown to home to the injured myocardium, however, transdifferentiation of Sca-1⁺ cells was accompanied by fusion with native cardiomyocytes [34]. *Side population (SP) cells* are of interest to the field of cardiac regeneration because they have been shown to be able to serve as progenitors for hematopoietic cells [35], skeletal muscle [36] and endothelium [18]. SP cells have been identified in the bone marrow and non-hematopoietic organs, including the heart [37] and are named after their ability to efflux the fluorescent vital dye Hoechst 33342 which is readily taken up by live cells where it binds to DNA [38]. SP cells fall within a separate population to the side of the remainder of analyzed cells on a dot plot of emission data collected by

fluorescence-activated cell sorting. The ability of SP cells to efflux Hoechst 33342 is dependent on the expression of the *Abcg2* protein, an ATP-binding cassette transporter [39]. *Abcg2*⁺ SP cells have the ability to express sarcomeric α -actinin when co-cultured with adult cardiomyocytes [37] and have been shown to participate in cardiac repair in mice subjected to cardiac cryoinjury [40]. **Cardiosphere-derived cells (CDCs)** from explant cultures of endomyocardial biopsy material are being tested for efficacy in averting heart failure following myocardial infarction [41–43]. Previous reports support the notion that CDCs directly regenerate cardiomyocytes and blood vessels [42, 44, 45]. CDCs injected into the infarct borderzone of SCID beige mice have been reported to improve left ventricular function [42]. CDCs have also been shown to secrete pro-survival and proangiogenic growth factors in vitro and in a murine cardiac cell therapy model [43]. In the prospective, randomized phase 1 “CARDiosphere-Derived aUTologous stem CELls to reverse ventricular dySfunction (CADUCEUS)” trial [46], patients randomized to CDC instead of standard therapy were injected with autologous CDCs into the infarct-related coronary artery 1.5–3 months following myocardial infarction. While statistically significant reduction in scar mass, increase in viable heart mass, regional contractility and regional systolic wall thickening were noted compared with controls at 6 months, no statistically significant improvements in hemodynamic function were found.

Epicardial Stem Cells

Another group of cells currently being studied is found in the epicardium, the outermost layer of the heart [4], and has been explored as a potential source of generating new cardiomyocytes [47]. As most other internal organs, the heart is covered by a mesothelium which consists of epicardial cells that migrate from the proepicardium, an outgrowth of the septum transversum, and spread over the surface of the heart during cardiac development [48, 49]. Epicardial cells have been reported to contribute to formation of cardiac blood vessels by undergoing epicardial-mesenchymal transition (EMT) and subsequent differentiation into myocardial stroma as well as vascular smooth muscle and coronary endothelial cells [50–52]. However, Red-Horse et al. recently identified sprouting from the sinus venosus as the major source of coronary vascular endothelial cells in mice [53]. Furthermore, several independent lineage tracing experiments of epicardium-derived progenitor cells (EPDCs) during cardiac development using progenitor markers such as *Tbx18* [51], *Wt1* [54], *Isl1* [33] and *Nkx2.5* [55], reported that a subset of EPDCs also differentiates into cardiomyocytes. Specifically, Cai and colleagues suggested that *Tbx18*⁻ expressing epicardium provides a substantial contribution to cardiomyocytes in the

ventricular septum as well as atrial and ventricular walls [51]. However, these findings were questioned by Christoffels and colleagues who demonstrated that *Tbx18* itself is, in fact, expressed in the myocardium from embryonic day (E) 10.5 to at least E14.5 [56], thereby limiting the conclusion that *Tbx18*⁺ epicardial cells contribute to the cardiomyocyte lineage in vivo. A genetic lineage study by Pu and colleagues indicated that *Wt1*^{Cre}-expressing epicardial cells differentiate into cardiomyocytes during normal heart development and are derived from progenitors that express transcription factors *Nkx2.5* and *Isl1* [52], suggesting that they are of the same developmental origin as multipotent cardiogenic progenitors [57, 58]. Interestingly, Zeng and colleagues recently demonstrated *Wt1* expression in the embryonic murine heart [59]. In contrast to the original study by Pu and colleagues [52], which found *Wt1* expression to be confined to the proepicardium and epicardium from E9.5 to E15.5, here, *Wt1* expression was confined to the epicardium only from E9.5 to E11.5 and began to be expressed in the myocardium at E12.5. However, *Wt1* expression did not colocalize with *Nkx2.5* [59], a well-characterized marker of early cardiomyocyte lineage [60]. Furthermore, Zeng and colleagues found robust *Tbx18* expression in myocardium from E11.5, and its expression colocalized with *Nkx2.5*. These data on *Tbx18* expression are in line with those previously reported by Christoffels et al. [56]. Taken together, the findings of Christoffels et al. and Zeng et al. raise doubts regarding the specificity of the Cre recombinase-based genetic lineage studies performed by Cai et al. [51] and Zhou et al. [52] and question the relevance of *Tbx18* and *Wt1* as epicardium-specific genetic markers.

A recent study by Katz et al. [61] demonstrated that the epicardium does not make significant contributions to the myocardium during development. Here, the authors employed fate mapping studies in mouse and chick, as well as in vitro analysis, to trace the fate of proepicardium-derived cells labeled with proepicardial markers *Scleraxis* (*Scx*) and *Semaphorin3D* (*Sema3D*) in an effort to answer the question whether the proepicardium contributes to the coronary endothelium. Previous data from chick and mouse lineage tracing studies conflict in that avian lineage tracing studies have established the proepicardium as a source of vascular smooth muscle and endothelial cells [62–66], whereas the aforementioned fate mapping studies in mice utilizing *Tbx18* and *Wt1* as proepicardial markers [51, 52] did not identify a significant proepicardial contribution to the endothelium. The authors showed here that *Scx* and *Sema3D* delineate proepicardial subcompartments which are largely nonoverlapping with *Tbx18*- and *Wt1*-expressing populations. It was demonstrated that both *Scx*⁺ and *Sema3D*⁺ epicardial cells give rise to endothelial cells, in addition to other cardiac fates including cardiomyocytes. However, only 6.6 % of *Scx*- and 0.36 % of *Sema3D*-lineage traced cells give rise to cardiomyocytes. On the one

hand, this study illustrates the complexity of the proepicardium, which consists of genetically distinct subcompartments that give rise to distinct yet partially overlapping cell fates, on the other hand, it demonstrates that the epicardium does not make significant contributions to the myocardium during development. Kikuchi et al. examined the developmental potential of epicardial tissue in a third model system, zebrafish, during embryonic development and injury-induced heart regeneration [67]. Their study provides convincing evidence that natural epicardial fates are limited to non-myocardial cell types in this key model system for embryonic heart development and function. It has previously been shown that zebrafish possess robust natural capacity for adult myocardial regeneration [68]. Surgical resection of the ventricular apex leads to significant proliferation of epicardial cells that subsequently incorporate into the regenerating tissue [69, 70]. While it is known that spared cardiomyocytes are activated and proliferate in response to myocardial injury and thus contribute significantly to cardiac regeneration in zebrafish [14, 69], Kikuchi et al. [67] aimed to examine whether epicardial cells differentiate into cardiomyocytes. Among several candidate genes screened for epicardial-specific expression, zebrafish *tcf21* was selected for use in subsequent Cre recombinase based genetic lineage studies, as it displayed epicardial-specific expression during development and regeneration and was never detected within cardiomyocytes, in contrast to *tbx18* and *wt1b*. *Tcf21* was originally identified as a basic helix-loop-helix transcription factor which is expressed in the proepicardium, epicardium and other mesoderm-derived tissues during murine embryonic development [71–74]. A transgenic zebrafish line in which *tcf21* regulatory sequences drive tamoxifen-inducible Cre recombinase was generated and crossed with the previously described *gata5:RnG* indicator line [71] to label cells with a nuclear localization signal-tagged EGFP after excision of loxP-flanked stop sequences. *Tcf21:CreER; gata5:RnG* double transgenic larvae were incubated with 4-hydroxytamoxifen (4-HT) at 3–5 days post fertilization (dpf), when proepicardium-derived epicardial cells have completely enveloped the developing zebrafish heart. An antibody against EGFP was used to increase sensitivity of detecting EGFP-labeled cells, and no cells that co-expressed the cardiomyocyte-specific markers myosin heavy chain or *Mef2* were labeled, ensuring specificity. Labeled larvae were allowed to mature to adults and EGFP immunofluorescence was subsequently assessed. While the ventricular and atrial surfaces as well as the ventricular subepicardial areas were covered with $\text{EGFP}^+\text{MHC}^-\text{Mef2}^-$ cells, such cells were not found in the inner trabecular myocardium. Genetic labeling with a second indicator line, $\beta\text{-act2:RSG}$, which was previously shown to label cardiomyocytes with high efficiency in combination with the *cmlc2:CreER* line [71], was performed using *tcf21:CreER; \beta-act2:RSG* animals treated with 4-HT as larvae, and showed no EGFP labeled cells within the heart. Of

note, it was found that larval *tcf21*⁺ epicardial cells contribute to perivascular cell types. These data indicate that the epicardium does not contribute to cardiac muscle during zebrafish development. The authors next assessed epicardial contributions during cardiac regeneration by growing 4-HT-labeled *tcf21:CreER; gata5:RnG* or *tcf21:CreER; \beta-act2:RSG* larvae and resecting ventricular apices at 4–5 months of age. Within 30 days post amputation (dpa), a substantial number of EGFP^+ cells was observed within *tcf21:CreER; gata5:RnG* animals, but without co-expression of MHC or *Mef2*. Instead, EGFP^+ cells resembled DsRed2^+ perivascular cells observed in regenerating tissue of the *tcf21:DsRed2* reporter line. No EGFP^+ cells were detected in *tcf21:CreER; \beta-act2:RSG* regenerates. Incubation of 3- to 4-month-old *tcf21:CreER; gata5:RnG* animals with 4-HT and subsequent assessment for EGFP^+ cells in 30dpa regenerates revealed EGFP-labeling in the majority of adult epicardial cells as well as many EPDCs and perivascular cells, yet no EGFP^+ cells with co-expression of myocardial markers were observed. Also, no EGFP^+ cardiomyocytes were found in regenerating tissue of *tcf21:CreER; \beta-act2:RSG* animals treated with 4-HT at adult ages. These findings indicate that the zebrafish epicardium is a source of perivascular support cells, but not cardiomyocytes, during heart regeneration. In summary, this important study which used *tcf21*, an epicardial-specific marker, for Cre recombinase-based genetic lineage studies in zebrafish, found that the epicardium contributes perivascular support cells, but not cardiomyocytes, during development and cardiac regeneration. Since these findings conflict with previous reports in mice which employed *Tbx18*- and *Wt1*- based genetic fate mapping of epicardial cells [51, 52], use of the murine counterpart of *tcf21* for genetic fate-mapping will help elucidate the natural potential of epicardial cells during vertebrate development. Furthermore, while the findings of Kikuchi et al. [67] indicate that epicardial cells are not a natural source of cardiomyocytes, it is possible that experimental manipulation can elicit a pro-myogenic potential in these cells.

Epicardial progenitor cells are currently an attractive target in cardiac regenerative medicine. However, the fact that EPDCs become dormant following embryonic development has been a great limitation regarding their use [75, 76]. Because EPDCs are of great clinical interest, recent efforts have been directed at reactivating or mobilizing EPDCs after ischemic heart injury such as myocardial infarction (M.I.).

Thymosin Beta 4 in Cardiac Repair

Reported Beneficial Effects

Recently, thymosin beta 4 (T β 4) has drawn significant attention in cardiac regenerative medicine. T β 4 is a polypeptide composed of 43 amino acid residues [77] and

member of the family of thymosin peptides that were initially isolated from the thymus, but have been shown to be present in other tissues as well [78]. While T β 4 is the major regulator of the actin cytoskeleton in mammalian cells, it has also been reported to promote stimulation of wound healing and hair growth [79]. Furthermore, T β 4 was detected in developing murine myocardium from E8.0 [80] and its temporal and spatial expression pattern during embryonic heart development from E9.5 to E12.5 was later characterized [6]. Based on these data, T β 4 has been implicated as necessary for cardiac development and angiogenesis [5]. Data also suggests that T β 4 has cardio-protective [6] and cardio-regenerative [7] effects in small and large animal models of myocardial infarction and ischemia/reperfusion [81]. In addition, *ex vivo* experiments have demonstrated that T β 4 can promote neo-vascularization [82, 83]. In response to injury, T β 4 is released by platelets, macrophages and other cell types to protect cells and tissues from further damage and reduce apoptosis, inflammation and microbial growth [84]. T β 4 is thought to exhibit its beneficial effects on tissue regeneration by paracrine mechanisms [79]. In the field of cardiovascular regenerative medicine, research efforts have focused especially on confirming the suggested cardio-protective and -regenerative effects of T β 4 in an effort to translate its use to clinical trials.

Were Hopes Premature?

Two recent reports have found contradictory results regarding the cardio-regenerative capacity of T β 4 [47, 85] and a third report even calls into question its previously suggested essential role in cardiac development and function [86].

Recently, Smart et al. [47] reported that priming with T β 4 before induction of myocardial infarction mobilizes EPDCs from the epicardium to the infarct zone where they begin to express markers specific for mature cardiomyocytes, such as cardiac Troponin T (cTnT), sarcomeric α -actinin ($S\alpha A$) and Connexin-43 (Cx43). Employing Cre-lox and transgenic mice strain technologies, the authors were able to trace EPDCs in which GFP and YFP expression is driven by the Wt1 promoter and hence monitor the fate of stimulated epicardial progenitors as they migrated into the myocardium. In addition, T β 4-induced GFP⁺ progenitor cells were transplanted into wild-type mice following induction of M.I. and the GFP⁺ cells appeared to differentiate into mature cardiomyocytes.

The mechanisms by which EPDCs are stimulated, mobilized and differentiated have yet to be defined. Furthermore, despite the elegant genetic fate-mapping approach employed in the study by Smart et al., demonstration of immunofluorescence data indicating expression of cardiac markers and calcium transients between YFP⁻ and YFP⁺ cells as proof of functional coupling of existing and “de novo” cardiomyocytes is insufficient evidence of having generated functional cardiomyocytes. A hallmark of any cell type that can differentiate

into a cardiomyocyte is the ability to beat. In order to circumvent any potential artifactual results, live imaging movies of beating cardiomyocytes are the only true test of cardiomyocyte differentiation. Thus, there is no conclusive data proving that T β 4 can induce “de novo” cardiomyocyte formation. The findings of Smart et al., provocative as they may seem, leave some unanswered questions that must be resolved in order to fully explore a viable translational path for T β 4.

An even more essential question than determining if T β 4 can drive differentiation of EPDCs into cardiomyocytes is whether use of T β 4 can be meaningfully translated into clinical practice. In stark contrast to the experimental design employed in the study by Smart et al. [47], administration of T β 4 before M.I. will not be feasible in clinical trials. Therefore, it would seem more plausible to focus on the potential benefits of T β 4 treatment after M.I. and evaluate its ability to induce differentiation of EPDCs into cardiomyocytes as well as its other reported cardioprotective properties in a more clinically relevant setting. Interestingly, Zhou et al. [85] addressed this very question in a recent report in which they asked whether T β 4 treatment after M.I. could reprogram EPDCs into cardiomyocytes and augment the epicardium’s response to injury. This study is of particular significance because the authors employed the same epicardium-specific inducible Cre-line for genetic fate mapping of EPDCs that was used in the study by Smart et al., i.e. WT1CreERT2⁺, obtained clinical grade T β 4 from the same source as Smart et al. and ensured similar systemic levels of T β 4 by administering multiple injections. The principal difference was the timing of T β 4 treatment, i.e. myocardial infarction was induced in the WT1CreERT2⁺ mice and T β 4 administered daily for 1 week as opposed to priming with T β 4 before induction of M.I. The fate of GFP-expressing EPDCs was analyzed 2 weeks post M.I. and the data confirmed the previously described cardio-protective properties of T β 4 [6, 83], namely significant reduction of infarct size, cardiac fibrosis, cardiomyocyte apoptosis and increased vessel density. Importantly, T β 4 treatment also augmented thickening of the epicardial layer. Thickening of the epicardial layer, which is comprised of EPDCs and epicardial cells, in response to M.I. was previously reported by the same group and thought to mediate the secretion of paracrine factors that mitigate myocardial injury and adverse cardiac remodeling [87]. This finding also proves that the T β 4 used in this study was biologically active. On the other hand, T β 4 treatment post M.I. did not mobilize EPDCs so they would migrate into the myocardium, nor did it direct their differentiation into cardiomyocytes. The authors concluded that, while T β 4 therapy post M.I. had an overall beneficial effect on the heart, it did not reprogram epicardial cells into cardiomyocytes.

These results raise the question why T β 4 priming before M.I. induces EPDCs to differentiate into cardiomyocytes,

while T β 4 treatment following M.I. does not. One possible explanation lies in the fact that myocardial injury alters epicardial cell properties and gene expression to a substantial degree. Following M.I., the angiogenic gene expression profile of epicardial cells remains largely unaltered when compared to the profile of EPDCs in the healthy heart, despite either up- or down-regulation of several angiogenic genes. However, gene expression of stromal cell-derived factor 1 (Sdf1) and monocyte chemoattractant protein 1 (Mcp1), both chemotactic factors for circulating cells active in angiogenesis [88, 89], are highly up-regulated by M.I. This indicates that expression of additional epicardial genes relevant to the myocardial injury response is significantly altered following M.I., which is in line with other reported pro-angiogenic properties of EPDCs and stresses their significant contribution to increased angiogenesis in the infarcted heart [81]. These altered properties might “lock” EPDCs in their role as a mediator of increased angiogenesis and thus impair epicardial cell plasticity in response to T β 4 treatment, preventing differentiation into cardiomyocytes. Myocardial infarction might also disrupt the architecture of an epicardial niche and thus deprive epicardial cells of factors required for reprogramming [85]. Another possible explanation why EPDCs do not differentiate into cardiomyocytes following M.I. may be because they also do not contribute significantly to cardiomyocyte formation during development [61, 67].

Taken together, T β 4 therapy in a clinically relevant model of myocardial infarction has been shown to exhibit overall cardio-protective effects, mostly mediated by augmenting the pro-angiogenic response of the epicardium following M.I. through as yet unknown molecular mechanisms. However, in this model, T β 4 has not been shown to be able to induce differentiation of EPDCs into cardiomyocytes, and hence, is not able to generate “de novo” cardiomyocytes.

In light of a very recent report by Banerjee et al. [86], it appears that T β 4 is dispensable for cardiac development and angiogenesis. Here, the authors generated two murine T β 4 knockout models in which T β 4 expression is ablated either globally or specifically in the heart and report that global ablation of T β 4 does not interfere with cardiac development. While developmental studies in mice suggested that T β 4 is required for embryonic heart development [5, 6, 80], Banerjee et al. [86] did not observe embryonic lethality, cardiac or other gross anatomic abnormalities in global T β 4 knockout mice. Histological examination of T β 4 knockout hearts at E14.5 did not reveal abnormal development of compact myocardium, detachment of epicardium or the presence of nodules on the epicardial surface, while these abnormalities were reported for E14.5 embryos in which T β 4 gene expression was silenced using T β 4-shRNA driven by Nkx2.5 (T β 4sh^{Nk}) [5]. Furthermore, Banerjee et al. did not observe changes in the epicardial

marker Wt1 in their T β 4 knockout embryos at E14.5. Since T β 4 was previously reported to induce mobilization of EPDCs and their differentiation into endothelial or smooth muscle cells (SMC) [5], the authors examined the microvasculature of embryonic T β 4 knockout hearts by immunocytochemistry and found no difference in the total number, formation and distribution of CD31-positive endothelial cells in the myocardium compared to control littermate hearts. Also, there was no difference in the pattern and distribution of α -smooth muscle actin⁺ SMC between T β 4 knockout and control hearts. Large vessels revealed normal smooth muscle and endothelial cell layers. These results indicate that global ablation of T β 4 does not alter the development of coronary vessels. Despite the suggested role of T β 4 in coronary angiogenesis [5], T β 4-knockout mice did not exhibit altered capillary bed density. As in embryonic hearts, adult hearts of T β 4 global knockout mice did not reveal morphological abnormalities or changes in expression of epicardial marker Wt1 or Tbx18. Echocardiographic analysis up to the age of 12 months did not reveal any significant difference in cardiac function between T β 4 global knockout mice and control littermates and no changes in survival were observed over a period of 12 months. As in T β 4 global knockout mice, cardiac-specific ablation of T β 4 did not result in embryonic lethality or cause abnormal cardiac function in adult animals.

Mouse embryos with heart-specific T β 4 deficiency by transgenic conditional RNA interference have been reported to exhibit significant cardiac developmental defects [5]. Specifically, floxed T β 4 short hairpin RNA (Tb4shRNA-flox) mice were crossed with one of two Cre-driver strains: Nkx2.5CreKI, which directs Cre expression throughout the majority of cardiomyocytes [90] or MLC2vCreKI, which directs Cre expression specifically to ventricular cardiomyocytes [91]. Banerjee et al. [86] did not observe any abnormalities in cardiac development in their murine global T β 4 knockout model. A possible explanation for these different outcomes is that shRNA-mediated knockdown of T β 4 may have had off-target effects [5, 86], i.e. unintended effects on gene expression mediated by RNA interference, a phenomenon associated with shRNA gene silencing [92, 93].

Previous reports suggested that T β 4 is required for cardiac development and angiogenesis [5] and has cardio-protective [6] and cardio-regenerative [7] effects in animal models of myocardial infarction. However, according to the report by Banerjee et al. [86], T β 4 appears dispensable for cardiac development and function and, while T β 4 treatment following myocardial infarction exhibits overall cardio-protective effects in a small animal model of myocardial infarction [85], it does not reprogram EPDCs into cardiomyocytes [85], as opposed to priming with T β 4 before induction of myocardial infarction [47].


Conclusions and Future Directions

Candidate Regenerative Cell Types and Factors

In light of the ever-growing number of reports that examine the regenerative potential of cardiac stem cells and trophic factors, and to avoid premature hopes of a certain candidate regenerative cell type or factor to be capable of mediating cardiac repair, it would be wise to ensure the respective cell or factor being tested meets minimum “quality standards”

before drawing the conclusion that it actually aids in cardiac regeneration. This could be done by following a multi-step approach to test whether the candidate progenitor cell exhibits certain essential qualities, such as the ability to form spontaneously beating cardiomyocytes *in vitro*, as this is the ultimate test for any cell under study for its potential to generate real, functional cardiomyocytes. For example, our own laboratory recently demonstrated that fetal cells selectively home to the injured maternal heart and undergo differentiation into endothelial cells, smooth muscle cells and

Fig. 1 Candidate regenerative factors and cell types. Isolation of putative cardiac progenitors that are either stimulated to adopt the cardiac fate or arise from transplanted cells should undergo *ex vivo* testing to document contractile ability using live imaging. Hemodynamic studies to support a true cardiac regenerative process should demonstrate sustained improvements over time



cardiomyocytes in a mouse model of mid-gestational myocardial injury. When isolated from the maternal heart, the fetal cells recapitulate these differentiation pathways and form beating cardiomyocytes in a fusion-independent manner [94]. If contractile ability is observed, the stimulated progenitors, newly generated cardiomyocytes or candidate factor(s) should be introduced into the infarcted heart to evaluate their ability to enhance cardiac structure, i.e. mitigate adverse remodeling following M.I. and to lead to sustained improvement of cardiovascular hemodynamics. Figure 1 depicts this suggested step-wise test approach. Clearly, monitoring cardiovascular hemodynamics for a time period of more than 28 days, which was the observational endpoint in the study by Smart et al. [47], is necessary to draw meaningful conclusions on whether the factor or cell type of interest induces true cardiac regeneration, as temporary improvements in left ventricular function may be attributable to paracrine effects [95, 96] that reduce cardiomyocyte hypoxia and necrosis rather than generate “de novo” cardiomyocytes, as is the case with T β 4.

Although the excitement about T β 4 as a modulator of cardiac repair has been lowered by recent reports, it is still worth investigating the molecular mechanisms by which T β 4 exhibits its cardio-protective effects and why it fails to induce EPDC plasticity when given post M.I. With a variety of promising cardiac progenitor cell types at hand and intense efforts in the field of cardiac regenerative medicine, the hunt is on for the cell type or drug that can repair the most vital of all organs, the heart.

Conflicts of interest The authors declare no competing conflicts of interest.

References

- Hoover-Plow, J., & Gong, Y. (2012). Challenges for heart disease stem cell therapy. *Vascular Health and Risk Management*, 8, 99–113.
- Leri, A., Kajstura, J., Anversa, P., & Frishman, W. H. (2008). Myocardial regeneration and stem cell repair. *Current Problems in Cardiology*, 33, 91–153.
- Bicknell, K. A., Coxon, C. H., & Brooks, G. (2007). Can the myocyte's cell cycle be reprogrammed? *Journal of Molecular and Cellular Cardiology*, 42, 706–721.
- Zhou, B., & Pu, W. T. (2012). Isolation and characterization of embryonic and adult epicardium and epicardium-derived cells. *Methods in Molecular Biology*, 843, 155–168.
- Smart, N., Risebro, C. A., Melville, A. A., et al. (2007). Thymosin beta 4 induces adult epicardial progenitor mobilization and neovascularization. *Nature*, 445, 177–182.
- Bock-Marquette, I., Saxena, A., White, M. D., DiMaio, J. M., & Srivastava, D. (2004). Thymosin β 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. *Nature*, 432, 466–472.
- Bock-Marquette, I., Srivastava, S., Pipes, G. C., et al. (2009). Thymosin β 4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. *Journal of Molecular and Cellular Cardiology*, 46, 728–738.
- Rubart, M., & Field, L. J. (2006). Cardiac regeneration: Repopulating the heart. *Annual Review of Physiology*, 68, 29–49.
- Bergmann, O., Bhardwaj, R. D., Bernard, S., et al. (2009). Evidence for cardiomyocyte renewal in humans. *Science*, 324, 98–102.
- Olivetti, G., Abbi, R., Quaini, F., et al. (1997). Apoptosis in the failing human heart. *The New England Journal of Medicine*, 336, 1131–1141.
- Olivetti, G., Giordano, G., Corradi, D., et al. (1995). Gender differences and aging: Effects on the human heart. *Journal of the American College of Cardiology*, 26, 1068–1079.
- Kajstura, J., Gurusamy, N., Ogórek, B., et al. (2010). Myocyte turnover in the aging human heart. *Circulation Research*, 107, 1374–1386.
- Hsieh, P. C., Segers, V. F., Davis, M. E., et al. (2007). Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. *Nature Medicine*, 13, 970–974.
- Jopling, C., Sleep, E., Raya, M., et al. (2010). Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature*, 464, 606–609.
- Nygren, J. M., Jovinge, S., Breitbach, M., et al. (2004). Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. *Nature Medicine*, 10, 494–501.
- Murry, C. E., Soonpaa, M. H., Reinecke, H., et al. (2004). Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. *Nature*, 428, 664–668.
- Orlic, D., Kajstura, J., Chimenti, S., et al. (2001). Bone marrow cells regenerate infarcted myocardium. *Nature*, 410, 701–705.
- Jackson, K. A., Majka, S. M., Wang, H., et al. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. *The Journal of Clinical Investigation*, 107, 1395–1402.
- Orlic, D., Kajstura, J., Chimenti, S., et al. (2001). Mobilized bone marrow cells repair the infarcted heart, improving function and survival. *Proceedings of the National Academy of Sciences of the United States of America*, 98, 10344–10349.
- Balsam, L. B., Wagers, A. J., Christensen, J. L., Kofidis, T., Weissman, I. L., & Robbins, R. C. (2004). Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature*, 428, 668–673.
- Lunde, K., Solheim, S., Aakhus, S., et al. (2005). Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. *Scandinavian Cardiovascular Journal*, 39, 150–158.
- Schachinger, V., Erbs, S., Elsässer, A., et al. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *The New England Journal of Medicine*, 355, 1210–1221.
- Wollert, K. C., Meyer, G. P., Lotz, J., et al. (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomized controlled clinical trial. *Lancet*, 364, 141–148.
- Mercola, M., Ruis-Lozano, P., & Schneider, M. D. (2011). Cardiac muscle regeneration: Lessons from development. *Genes & Development*, 25, 299–309.
- Beltrami, A. P., Barlucchi, L., Torella, D., et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell*, 114, 763–776.
- Bearzi, C., Rota, M., Hosoda, T., et al. (2007). Human cardiac stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, 104, 14068–14073.

27. Dawn, B., Stein, A. B., Urbanek, K., et al. (2005). Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. *Proceedings of the National Academy of Sciences of the United States of America*, *102*, 3766–3771.
28. Tang, X. L., Rokosh, G., Sanganalmath, S. K., et al. (2010). Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation*, *121*, 293–305.
29. Rota, M., Padin-Iruegas, M. E., Misao, Y., et al. (2008). Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. *Circulation Research*, *103*, 107–116.
30. Bolli, R., Chugh, A. R., D'Amario, D., et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. *Lancet*, *378*, 1847–1857.
31. Laugwitz, K. L., Moretti, A., Lam, J., et al. (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature*, *433*, 647–653.
32. Domian, I. J., Chiravuri, M., van der Meer, P., et al. (2009). Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. *Science*, *326*, 426–429.
33. Moretti, A., Caron, L., Nakano, A., et al. (2006). Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell*, *127*, 1151–1165.
34. Oh, H., Bradfute, S. B., Gallardo, T. D., et al. (2003). Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. *Proceedings of the National Academy of Sciences of the United States of America*, *100*, 12313–12318.
35. Asakura, A., & Rudnicki, M. A. (2002). Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. *Experimental Hematology*, *30*, 1339–1345.
36. Gussoni, E., Soneoka, Y., Strickland, C. D., et al. (1999). Dystrophin expression in the mdx mouse restored by stem cell transplantation. *Nature*, *401*, 390–394.
37. Martin, C. M., Meeson, A. P., Robertson, S. M., et al. (2004). Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. *Developmental Biology*, *265*, 262–275.
38. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *The Journal of Experimental Medicine*, *183*, 1797–1806.
39. Zhou, S., Schuetz, J. D., Bunting, K. D., et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nature Medicine*, *7*, 1028–1034.
40. Martin, C. M., et al. (2004). Abcg2 cardiac stem cell population participates in repair of adult mouse and human heart. *Supplement Circulation* *110* [Abstract no. 811] abstract citation.
41. Messina, E., De Angelis, L., Frati, G., et al. (2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circulation Research*, *95*, 911–921.
42. Smith, R. R., Barile, L., Cho, H. C., et al. (2007). Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. *Circulation*, *115*, 896–908.
43. Chimenti, I., Smith, R. R., Li, T. S., et al. (2010). Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circulation Research*, *106*, 971–980.
44. Tang, Y. L., Zhu, W., Cheng, M., et al. (2009). Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. *Circulation Research*, *104*, 1209–1216.
45. Takehara, N., Tsutsumi, Y., Tateishi, K., et al. (2008). Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. *Journal of the American College of Cardiology*, *52*, 1858–1865.
46. Makkar, R. R., Smith, R. R., Cheng, K., et al. (2012). Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. *Lancet*, *379*, 895–904.
47. Smart, N., Bollini, S., Dubé, K. N., et al. (2011). *De novo* cardiomyocytes from within the activated adult heart after injury. *Nature*, *474*, 640–644.
48. Manner, J., Perez-Pomares, J. M., Macias, D., & Munoz-Chapuli, R. (2001). The origin, formation and developmental significance of the epicardium: A review. *Cells, Tissues, Organs*, *169*, 89–103.
49. Wessels, A., & Perez-Pomares, J. M. (2004). The epicardium and epicardially derived cells (EPDCs) as cardiac stem cells. *The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology*, *276*, 43–57.
50. Wilm, B., Ipenberg, A., Hastie, N. D., Burch, J. B., & Bader, D. M. (2005). The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. *Development*, *132*, 5317–5328.
51. Cai, C. L., Martin, J. C., Sun, Y., et al. (2008). A myocardial lineage derives from Tbx18 epicardial cells. *Nature*, *454*, 104–108.
52. Zhou, B., Ma, Q., Rajagopal, S., et al. (2008). Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. *Nature*, *454*, 109–113.
53. Red-Horse, K., Ueno, H., Weissman, I. L., & Krasnow, M. A. (2010). Coronary arteries form by developmental reprogramming of venous cells. *Nature*, *464*, 549–553.
54. Von Gise, A., Zhou, B., Honor, L. B., Ma, Q., Petryk, A., & Pu, W. T. (2011). Wt1 regulates epicardial epithelial to mesenchymal transition through β -catenin and retinoic acid signaling pathways. *Developmental Biology*, *356*, 421–431.
55. Prall, O. W., Menon, M. K., Solloway, M. J., et al. (2007). An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. *Cell*, *128*, 947–959.
56. Christoffels, V. M., Grieskamp, T., Norden, J., Mommersteeg, M. T., Rudat, C., & Kispert, A. (2009). Tbx18 and the fate of epicardial progenitors. *Nature*, *458*, E8–E9.
57. Martin-Puig, S., Wang, Z., & Chien, K. R. (2008). Lives of a heart cell: Tracing the origins of cardiac progenitors. *Cell Stem Cell*, *2*, 320–331.
58. Laugwitz, K. L., Moretti, A., Caron, L., Nakano, A., & Chien, K. R. (2008). Islet1 cardiovascular progenitors: A single source for heart lineages? *Development*, *135*, 193–205.
59. Zeng, B., Ren, X. F., Cao, F., Zhou, X. Y., & Zhang, J. (2011). Developmental patterns and characteristics of epicardial cell markers Tbx18 and Wt1 in murine embryonic heart. *Journal of Biomedical Science*, *18*, 67.
60. Harvey, R. P. (1996). NK-2 homeobox genes and heart development. *Developmental Biology*, *178*, 203–216.
61. Katz, T. C., Singh, M. K., Degenhardt, K., et al. (2012). Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. *Developmental Cell*, *22*, 639–650.
62. Mikawa, T., & Gourdie, R. G. (1996). Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. *Developmental Biology*, *174*, 221–232.
63. Manner, J. (1999). Does the subepicardial mesenchyme contribute myocardioblasts to the myocardium of the chick embryo heart? a quail-chick chimera study tracing the fate of the epicardial primordium. *The Anatomical Record*, *255*, 212–226.
64. Gourdie, R. G., Cheng, G., Thompson, R. P., & Mikawa, T. (2000). Retroviral cell lineage analysis in the developing chick heart. *Methods in Molecular Biology*, *135*, 297–304.
65. Perez-Pomares, J. M., Carmona, R., Gonzalez-Iriarte, M., Atencia, G., Wessels, A., & Munoz-Chapuli, R. (2002). Origin of coronary

- endothelial cells from epicardial mesothelium in avian embryos. *International Journal of Developmental Biology*, 46, 1005–1013.
66. Guadix, J. A., Carmona, R., Munoz-Chapuli, R., & Perez-Pomares, J. M. (2006). In vivo and in vitro analysis of the vasculogenic potential of avian proepicardial and epicardial cells. *Developmental Dynamics*, 235, 1014–1026.
 67. Kikuchi, K., Gupta, V., Wang, J., et al. (2011). Tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. *Development*, 138, 2895–2902.
 68. Poss, K. D., Wilson, L. G., & Keating, M. T. (2002). Heart regeneration in zebrafish. *Science*, 298, 2188–2190.
 69. Lepilina, A., Coon, A. N., Kikuchi, K., et al. (2006). A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. *Cell*, 127, 607–619.
 70. Kim, J., Wu, Q., Zhang, Y., et al. (2010). PDGF signaling is required for epicardial function and blood vessel formation in regenerating zebrafish hearts. *Proceedings of the National Academy of Sciences of the United States of America*, 107, 17206–17210.
 71. Kikuchi, K., Holdway, J. E., Werdich, A. A., et al. (2010). Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. *Nature*, 464, 601–605.
 72. Hidai, H., Bardales, R., Goodwin, R., Quertermous, T., & Quertermous, E. E. (1998). Cloning of capsulin, a basic helix-loop-helix factor expressed in progenitor cells of the pericardium and the coronary arteries. *Mechanisms of Development*, 73, 33–43.
 73. Lu, J., Richardson, J. A., & Olson, E. N. (1998). Capsulin: A novel bHLH transcription factor expressed in epicardial progenitors and mesenchyme of visceral organs. *Mechanisms of Development*, 73, 23–32.
 74. Robb, L., Mifsud, L., Hartley, L., et al. (1998). Epicardin: A novel basic helix-loop-helix transcription factor gene expressed in epicardium, branchial arch myoblasts, and mesenchyme of developing lung, gut, kidney, and gonads. *Developmental Dynamics*, 213, 105–113.
 75. Vieira, J. M., & Riley, P. R. (2011). Epicardium-derived cells: A new source of regenerative capacity. *Heart*, 97, 15–19.
 76. Laflamme, M. A., & Murry, C. E. (2011). Heart regeneration. *Nature*, 473, 326–335.
 77. Low, T. L., & Goldstein, A. L. (1982). Chemical characterization of thymosin beta 4. *The Journal of Biological Chemistry*, 257, 1000–1006.
 78. Goldstein, A. L. (2007). History of the discovery of the thymosins. *Annals of the New York Academy of Sciences*, 1112, 1–13.
 79. Mannherz, H. G., & Hannappel, E. (2009). The beta-thymosins: Intracellular and extracellular activities of a versatile actin binding protein family. *Cell Motility and the Cytoskeleton*, 66, 839–851.
 80. Smart, N., Hill, A. A., Cross, J. C., & Riley, P. R. (2002). A differential screen for putative targets of the bHLH transcription factor Hand1 in cardiac morphogenesis. *Mechanisms of Development*, 119(Suppl 1), S65–S71.
 81. Hinkel, R., El-Aouni, C., Olson, T., et al. (2008). Thymosin Beta 4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. *Circulation*, 117, 2232–2240.
 82. Grant, D. S., Rose, W., Yaen, C., Goldstein, A., Martinez, J., & Kleinman, H. (1999). Thymosin beta 4 enhances endothelial cell differentiation and angiogenesis. *Angiogenesis*, 3, 125–135.
 83. Riley, P. R., & Smart, N. (2009). Thymosin beta 4 induces epicardium-derived neovascularization in the adult heart. *Biochemical Society Transactions*, 37, 1218–1220.
 84. Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β 4: A multi-functional regenerative peptide. Basic properties and clinical applications. *Expert Opinion on Biological Therapy*, 12, 37–51.
 85. Zhou, B., Honor, L. B., Ma, Q., et al. (2012). Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, 52, 43–47.
 86. Banerjee, I., Zhang, J., Moore-Morris, T., et al. (2012). Thymosin beta 4 is dispensable for murine cardiac development and function. *Circulation Research*, 110, 456–464.
 87. Zhou, B., Honor, L. B., He, H., et al. (2011). Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. *The Journal of Clinical Investigation*, 121, 1894–1904.
 88. Deshane, J., Chen, S., Caballero, S., et al. (2007). Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. *The Journal of Experimental Medicine*, 204, 605–618.
 89. Niu, J., Azfer, A., Zhelyabovska, O., Fatma, S., & Kolattukudy, P. E. (2008). Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). *Journal of Biological Chemistry*, 283, 14542–14551.
 90. Moses, K., DeMayo, F., Braun, R., Reecy, J., & Schwartz, R. (2001). Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. *Genesis*, 31, 176–180.
 91. Chen, J., Kubalak, S. W., Minamisawa, S., et al. (1998). Selective requirement of myosin light chain 2v in embryonic heart function. *Journal of Biological Chemistry*, 273, 1252–1256.
 92. Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009). siRNA vs. shRNA: Similarities and differences. *Advanced Drug Delivery Reviews*, 61, 746–759.
 93. Singh, S., Narang, A. S., & Mahato, R. I. (2011). Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. *Pharmaceutical Research*, 28, 2996–3015.
 94. Kara, R. J., Bolli, P., Karakikes, I., et al. (2012). Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. *Circulation Research*, 110, 82–93.
 95. Passier, R., van Laake, L. W., & Mummery, C. L. (2008). Stem-cell-based therapy and lessons from the heart. *Nature*, 453, 322–329.
 96. Heil, M., Ziegelhoeffer, T., Mees, B., & Schaper, W. (2004). A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. *Circulation Research*, 94, 573–574.